Piper Sandler analyst David Westenberg lowered the firm’s price target on Exact Sciences (EXAS) to $75 from $85 following quarterly ...

Artisan Mid Cap Fund highlighted stocks like Exact Sciences Corporation (NASDAQ:EXAS) in the third quarter 2024 investor letter. Exact Sciences Corporation (NASDAQ:EXAS) provides cancer screening ...

Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.

Exact Sciences' Q3 earnings report has led to a ... On the other hand, long-term, management expects the competition to intensify, warning that: Newer screening technologies include liquid ...

Exact Sciences Corp ( (EXAS) ) has released its Q3 earnings. Here is a breakdown of the information Exact Sciences Corp presented to its ...

Warning! GuruFocus has detected 5 Warning Sign with EXAS. Exact Sciences Corporation (NASDAQ:EXAS), a leader in cancer screening and diagnostic tests, has recently filed its 10-Q report on November 5, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The biomedical giant best known for its Cologuard at-home colon cancer screening test reported a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million.

Shares of Exact Sciences tumbled after the company cut its full-year outlook and posted third-quarter results that missed estimates. The stock fell 29%, to $50.51, in after-hours trading Tuesday.

Exact Sciences Corp showcases robust revenue growth amidst operational challenges. Innovative cancer screening and diagnostic tests position the company at the forefront of the healthcare industry.